The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $0.59 in the prior trading day, Cognition Therapeutics Inc (NASDAQ: CGTX) closed at $0.67, up 13.93%. In other words, the price has increased by $13.93 from its previous closing price. On the day, 4.03 million shares were traded. CGTX stock price reached its highest trading level at $0.6996 during the session, while it also had its lowest trading level at $0.5555.
Ratios:
Our goal is to gain a better understanding of CGTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.09 and its Current Ratio is at 2.09. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 19, 2024, Upgraded its rating to Buy and sets its target price to $1.50 from $1 previously.
On November 03, 2021, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $22.Oppenheimer initiated its Outperform rating on November 03, 2021, with a $22 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 31 ’25 when Ricciardi Lisa bought 38,851 shares for $0.77 per share. The transaction valued at 30,001 led to the insider holds 38,851 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGTX now has a Market Capitalization of 41374128 and an Enterprise Value of 25581158.
Stock Price History:
The Beta on a monthly basis for CGTX is 1.00, which has changed by 0.016768336 over the last 52 weeks, in comparison to a change of 0.20277917 over the same period for the S&P500. Over the past 52 weeks, CGTX has reached a high of $1.29, while it has fallen to a 52-week low of $0.22. The 50-Day Moving Average of the stock is 49.67%, while the 200-Day Moving Average is calculated to be 35.60%.
Shares Statistics:
The stock has traded on average 7.43M shares per day over the past 3-months and 4597410 shares per day over the last 10 days, according to various share statistics. A total of 61.97M shares are outstanding, with a floating share count of 49.82M. Insiders hold about 19.35% of the company’s shares, while institutions hold 9.08% stake in the company. Shares short for CGTX as of 1752537600 were 7414526 with a Short Ratio of 1.00, compared to 1749772800 on 1538143. Therefore, it implies a Short% of Shares Outstanding of 7414526 and a Short% of Float of 13.319999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Cognition Therapeutics Inc (CGTX) is the result of assessments by 4.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.06 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.36 and -$0.44 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.28, with 3.0 analysts recommending between -$0.18 and -$0.37.
